輝瑞(PFE.US)公佈Etrasimod治療潰瘍性結腸炎的三期臨牀試驗的積極結果
格隆匯3月29日丨近日,輝瑞(PFE.US)公佈了一項iii期臨牀研究的積極結果。該研究關於一種口服、每日一次的選擇性sphingosine 1-phosphate (S1P)受體調節劑,用於治療中度至重度活動性潰瘍性結腸炎(UC)。3月23日,輝瑞公佈在ELEVATE UC 12試驗結果的積極數據。與安慰劑相比,伊拉西mod患者在12周和52周臨牀緩解的共同主要終點上取得了統計學上顯著的改善。Etrasimod的安全性也與之前的研究一致,包括2期OASIS試驗。Etrasimod是由Arena製藥公司開發的,該公司最近被輝瑞公司收購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.